

Emale

1617



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q62780

Komei WASHINO, et al.

Appln. No.: 09/744,550

Group Art Unit: 1617

Confirmation No.: 9592

Examiner: Lauren Q. WELLS

Filed: January 26, 2001

For: DRUGS FOR MEDICAL USE ENABLING NUCLEAR MAGNETIC RESONANCE
DIAGNOSIS BY SCALAR COUPLING

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, along with a copy of a Communication (Supplementary European Search Report) citing such documents in a corresponding foreign application.

The present Information Disclosure Statement is being filed after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes

INFORMATION DISCLOSURE STATEMENT.

U.S. Appln. No.: 09/744,550

prosecution in the application (whichever is earlier), and therefore Applicant is filing concurrently herewith a Statement Under 37 C.F.R. § 1.97(e). No fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Sheldon I. Landsman
Registration No. 25,430

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: April 21, 2004

Substitute for Form 1449 A & B/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Application Number	09/744,550
Confirmation Number	9592
Filing Date	January 26, 2001
First Named Inventor	Komei WASHINO
Art Unit	1617
Examiner Name	Lauren Q. WELLS
Attorney Docket Number	Q62780

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Balaban R. S. et al: "Nitrogen-14 nuclear magnetic resonance spectroscopy of mammalian tissues", The American Journal of Physiology, Nov. 1983, vol. 245, no. 5 Pt 1, November 1983 (1983-11), pages C439-C444, XP0008028414, ISSN: 0002-9513.	
		Neurohr K. J. et al: "In vivo carbon-13 nuclear magnetic resonance studies of heart metabolism", Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 6 I, 1983, pages 1603-1607, XP0008028439.	
		Velan S. S. et al: "Monitoring the therapeutic response of tumours by nuclear magnetic resonance spectroscopy", Medical Science Research, United Kingdom, vol. 19, no. 18, 1991, pages 609-611, XP0008028438, ISSN: 0269-8951.	
		Griffin J. L. et al: "Delayed labeling of brain glutamate after an intra-arterial [¹³ C] glucose bolus: evidence for aerobic metabolism of guinea pig brain glycogen store", Biochimica et Biophysica Acta., vol. 1450, no. 3, July 8, 1999 (1999-07-08), pages 297-307, XP002272685, ISSN: 0006-3002.	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q62780

Komei WASHINO, et al.

Appln. No.: 09/744,550

Group Art Unit: 1617

Confirmation No.: 9592

Examiner: Lauren Q. WELLS

Filed: January 26, 2001

For: DRUGS FOR MEDICAL USE ENABLING NUCLEAR MAGNETIC RESONANCE
DIAGNOSIS BY SCALAR COUPLING

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860


Sheldon I. Landsman
Registration No. 25,430

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: April 21, 2004